Innate Pharma SA Profit Loss
Innate Pharma SA (IPHYF) reported Profit Loss of -EUR 49.18 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Income Statement
ifrs-full:ProfitLoss · last filed 2026-04-01
| Period end | Profit Loss 6 month | Profit Loss 12 month |
|---|---|---|
| 2025-12-31 | -49.18M EUR 20-F · filed 2026-04-01 | |
| 2025-06-30 | -21.34M EUR 6-K · filed 2025-09-17 | |
| 2024-12-31 | -49.47M EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | -24.76M EUR 6-K · filed 2025-09-17 | |
| 2023-12-31 | -7.57M EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 1.72M EUR 6-K · filed 2024-09-12 | |
| 2022-12-31 | -58.10M EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | 6.30M EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | -52.81M EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | -23.72M EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | -63.98M EUR 20-F · filed 2023-04-06 | |
| 2020-06-30 | -10.33M EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | -20.76M EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | 3.05M EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | -48.38M EUR 20-F · filed 2020-04-24 |